Upstream Bio (UPB) Preferred Stock Liabilities (2023 - 2024)
Upstream Bio's (UPB) quarterly Preferred Stock Liabilities came in at $380.9 million in Q3 2024, up 64.93% year-on-year from $230.9 million in Q4 2023, and little changed quarter-over-quarter from $380.9 million in Q2 2024.
Upstream Bio (UPB) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Upstream Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $380.9 million for Q3 2024.
- On a quarterly basis, Preferred Stock Liabilities rose 64.93% year-over-year to $380.9 million in Q3 2024; TTM through Sep 2024 was $380.9 million, a 64.93% increase from a year earlier, with the FY2023 full-year figure at $230.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $380.9 million in Q3 2024 per UPB's latest filing, from $380.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $380.9 million in Q2 2024 and bottomed at $230.9 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Upstream Bio | 347.73 Mn | 347.73 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 380.87 Mn |
| Jun 30, 2024 | 380.87 Mn |
| Mar 31, 2024 | 230.94 Mn |
| Dec 31, 2023 | 230.94 Mn |
| Sep 30, 2023 | 230.94 Mn |